Navigation Links
Renal denervation gives better outcomes than drugs in advanced heart failure
Date:8/27/2012

Munich, Germany August 27 2012: Renal denervation leads to better outcomes than standard drug treatment in patients with advanced heart failure, according to research presented at ESC Congress 2012. The results of the Olomouc I pilot study were presented by Dr Milo Tborsk from the University Hospital Olomouc.

Renal denervation does not involve any pharmacological treatment. It is a multiple application of radiofrequency energy using a thin catheter via the femoral artery and a long-term "denervation" of the sympathetic nerves around the renal arteries. "This is done to prevent an increased excretion of the substances leading to heart failure," said Dr Tborsk.

The aim of this pilot study was to compare the outcomes of patients with advanced heart failure receiving standard pharmacological treatment or renal denervation. Over the period of one year, 26 patients were treated with renal denervation and standard pharmacotherapy and 25 patients received standard drug treatment with beta-blockers, ACE inhibitors or ARBs and diuretics.

After one year contractile function of the left side of the heart improved in patients treated with renal denervation from 2512% to 3114% (p<0.01).

There was no change in contractile function of the left side of the heart in patients who received standard drug treatment. "The improvement of the contractile function of the left side of the heart by more than 10% in patients after renal denervation was a surprise," said Dr Tborsk. "This parameter has practically not changed in patients treated by the classic drugs. The difference in response might be explained by a continuous decrease of the renal sympathetic activity in the complex pathophysiology of heart failure."

During the one year follow-up, 8 patients treated with renal denervation were hospitalized due to heart failure compared to 18 patients treated with standard drug therapy. Dr Tborsk said: "Twice the number of patients treated by classic pharmacological therapy were taken to hospital due to heart failure."

The disadvantage of denervation, as with any invasive treatment, is the potential for subsequent complications. "We have registered two complications the formation of a fistula by the artery and the vein in the place of puncture and the formation of thrombi despite all safety measures being adhered to," said Dr Tborsk. "We have successfully removed both complications by a surgical revision and thromboaspiration."

The findings indicate that renal denervation may be a non-pharmacological alternative for the treatment of patients with advanced heart failure and may help stabilise the disease. "Renal denervation is particularly suited for patients without an extensive scar after myocardial infarction and whose heart rate increases when they are treated with the maximum tolerated dose of beta-blockers," added Dr Tborsk.

He concluded: "The long-term effects of renal denervation should be confirmed in a large international randomised study."


'/>"/>

Contact: ESC Press Office
press@escardio.org
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Broken heart syndrome protects the heart from adrenaline overload
2. Newborn Screening May Miss Adrenal-Gland Disorder
3. Human Airways Brush Mechanism Gives Clues to Lung Diseases
4. FDA Gives Nod to First Drug for Diabetic Eye Disease
5. FDA Gives Nod to New Breast Cancer Drug
6. Study Gives First Evidence That Adult Human Lungs Can Regrow
7. OC Firm Gives Back to Young Athletes
8. Aurora Dentist Gives Patients Big Savings With Teeth in a Day Implants
9. Killer stainless steel: New process gives icon of cleanliness antibacterial coating
10. Amazon Tribe Gives Clues to Heart-Healthy Lifestyles
11. FDA Panel Gives Blessing to New Weight-Loss Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... in the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity ... a rare and deadly chromosome abnormality. , After struggling since birth with several ...
(Date:10/13/2017)... ... , ... While it’s often important to take certain medications during the night, ... has identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX ... eliminates the need to turn on a light when taking medication during the night, ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
Breaking Medicine Technology: